CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. clinical trials

A subsidiary of CSPC Pharmaceutical Group Limited

The registry lists 27 studies whose lead sponsor is CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2026.

Studies

Recruiting first, then most recently updated. Showing 27 of 27. All CSPC Pharmaceutical Group Limited studies →

• Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial HypercholesterolemiaRecruitingNCT07591298Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaRecruitingNCT07695597Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)RecruitingNCT07465263Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)Not yet recruitingNCT07640217Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionNot yet recruitingNCT07635914Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2061RecruitingNCT07241910Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.Not yet recruitingNCT07547384Not applicable

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaRecruitingNCT07421297Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Bioequivalence Study of PP3M in Patients With SchizophreniaRecruitingNCT07493551Not applicable

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyNot yet recruitingNCT07421284Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2070 InjectionRecruitingNCT07241923Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer PatientsRecruitingNCT07096869Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Study of SYH2062 Injection in Healthy Chinese VolunteersRecruitingNCT06842537Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingNCT06543966Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid LeukemiaNot yet recruitingNCT06182592Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for InjectionRecruitingNCT05801835Not applicable

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergencyNot yet recruitingNCT05783557Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing TreatmentNot yet recruitingNCT05717764Phase 3

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaCompletedNCT07421232Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT07268430Not applicable

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053CompletedNCT06229548Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)CompletedNCT05551598Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Bioequivalence of Amphotericin B Liposome for InjectionCompletedNCT05913921Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisWithdrawnNCT05496894Phase 2

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MMStatus unknownNCT05052970Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy SubjectsCompletedNCT04993222Phase 1

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML PatientsStatus unknownNCT04920500Not applicable

  Sponsor listed in the registry: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.